?-Secretase inhibitors and modulators for Alzheimer's disease

被引:115
|
作者
Wolfe, Michael S. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
active site; allosteric sites; amyloid; chemical probes; docking site; protease; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TARGET GAMMA-SECRETASE; C-TERMINAL FRAGMENT; BETA-PROTEIN; THERAPEUTIC TARGET; ACTIVE-SITE; PRESENILIN; DISCOVERY;
D O I
10.1111/j.1471-4159.2011.07501.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
-Secretase is a membrane embedded aspartyl protease complex with presenilin as the catalytic component. Along with beta-secretase, this enzyme produces the amyloid beta-protein of Alzheimers disease (AD) from the amyloid beta-protein precursor. Because of its key role in the pathogenesis of AD, ?-secretase has been a prime target for drug discovery, and many inhibitors of this protease have been developed. The therapeutic potential of these inhibitors is virtually negated by the fact that beta-secretase is an essential part of the Notch signaling pathway, rendering the compounds unacceptably toxic upon chronic exposure. However, these compounds have served as useful chemical tools for biological investigations. In contrast, beta-secretase modulators continue to be of keen interest as possible AD therapeutics. These modulators either shift amyloid beta-protein production to shorter, less pathogenic peptides or inhibit the proteolysis of amyloid beta-protein precursor selectively compared to that of Notch. The various chemical types of inhibitors and modulators will be discussed, along with their use as probes for basic biology and their potential as AD therapeutics.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 50 条
  • [31] The Development of Anti-Amyloid Therapy for Alzheimer’s DiseaseFrom Secretase Modulators to Polymerisation Inhibitors
    Paul S. Aisen
    [J]. CNS Drugs, 2005, 19 : 989 - 996
  • [32] γ-Secretase in Alzheimer’s disease
    Ji-Yeun Hur
    [J]. Experimental & Molecular Medicine, 2022, 54 : 433 - 446
  • [33] Recent developments of structure based β-secretase inhibitors for Alzheimer's disease
    Ghosh, AK
    Kumaragurubaran, N
    Tang, J
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (16) : 1609 - 1622
  • [34] BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
    Ghosh, Arun K.
    Osswald, Heather L.
    [J]. CHEMICAL SOCIETY REVIEWS, 2014, 43 (19) : 6765 - 6813
  • [35] Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
    Kumar, Devendra
    Ganeshpurkar, Ankit
    Kumar, Dileep
    Modi, Gyan
    Gupta, Sanjeev Kumar
    Singh, Sushil Kumar
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 148 : 436 - 452
  • [36] In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease
    Semighini, Evandro Pizeta
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 86 (03) : 284 - 290
  • [37] Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease
    Bulic, Bruno
    Ness, Julia
    Hahn, Stefanie
    Rennhack, Andreas
    Jumpertz, Thorsten
    Weggen, Sascha
    [J]. CURRENT NEUROPHARMACOLOGY, 2011, 9 (04) : 598 - 622
  • [38] Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease
    Huang, Xianhai
    Zhou, Wei
    Liu, Xiaoxiang
    Li, Hongmei
    Sun, George
    Mandal, Mihirbaran
    Vicarel, Monica
    Zhu, Xiaohong
    Bennett, Chad
    McCraken, Troy
    Pissarnitski, Dmitri
    Zhao, Zhiqiang
    Cole, David
    Gallo, Gioconda
    Zhu, Zhaoning
    Palani, Anandan
    Aslanian, Robert
    Clader, John
    Czarniecki, Michael
    Greenlee, William
    Burnett, Duane
    Cohen-Williams, Mary
    Hyde, Lynn
    Song, Lixin
    Zhang, Lili
    Chu, Inhou
    Buevich, Alexei
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (11): : 931 - 935
  • [39] Lipid bilayer position and orientation of novel carprofens, modulators of γ-secretase in Alzheimer's disease
    Salnikov, Evgeniy
    Drung, Binia
    Fabre, Gabin
    Itkin, Anna
    Otyepka, Michal
    Dencher, Norbert A.
    Schmidt, Boris
    Hauss, Thomas
    Trouillas, Patrick
    Bechinger, Burkhard
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2018, 1860 (11): : 2224 - 2233
  • [40] Pivotal trials for β-secretase inhibitors in Alzheimer's
    Sheridan, Cormac
    [J]. NATURE BIOTECHNOLOGY, 2015, 33 (02) : 115 - 116